Novartis’ Pluvicto supply ‘fully unconstrained,’ eyes manufacturing expansion
Novartis says that access to Pluvicto is now “fully unconstrained” as the pharma giant plans for manufacturing expansions to ensure a steady supply of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
